This Valeant Chart Looks Great (Just Don't Try to Measure It)
This article is for subscribers only.
Valeant Pharmaceuticals International Inc. told investors Wednesday that new products will be a key part of the drugmaker’s turnaround strategy. Just don’t ask for too many details on the numbers.
A slide labeled “Return to Growth” lays out colorful bars representing the company’s sales expectations. This year represents a nadir, and in coming years, a smooth ascent is projected. The Valeant’s base business will grow, and “new products” -- currently a small proportion of its overall revenue -- will make up roughly a third of sales.